AnalystsEric SchmidtEric Schmidt's Stock Forecasts
AnalystsEric Schmidt
Sectors:
Industries:
Analyst Ranking
Bottom 29%
#3709 out of 5206 analysts
Average Return
-0.11%
Win Rate
38%6 out of 16
Risk vs Reward
Poor
Good
Eric Schmidt's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
G1 Therapeutics IncGTHX | +129.24% | $17.99 | $41.24 | 2017-06-12 - 2018-06-12 | Buy |
Bioverativ IncBIVV | +68.97% | $62.13 | $104.98 | 2017-07-10 - 2018-03-08 | Buy |
Avidity Biosciences IncRNAM | +34.04% | $23.97 | $32.13 | 2024-03-14 - 2025-03-13 | Strong Buy |
Bicara Therapeutics IncBCAX | +31.76% | $13.35 | $17.59 | 2025-03-13 - 2026-03-02 | Strong Buy |
Vertex Pharmaceuticals IncVRTX | +30.46% | $373.50 | $487.25 | 2023-10-17 - 2024-10-16 | Strong Buy |
Eric Schmidt Analyst Color
Get additional color on Eric Schmidt's coverage of popular stocks
Eric Schmidt's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Legend Biotech CorpLEGN | 3 | Strong Buy | $74.00 | +301.30% | Maintains | 3 months ago |
Arcellx IncACLX | 1 | Hold | $88.00 | -22.84% | Assumes | 5 months ago |
Avidity Biosciences IncRNAM | 5 | Strong Buy | $96.00 | +550.85% | Reiterates | 8 months ago |
Bicara Therapeutics IncBCAX | 1 | Strong Buy | $13.01 | -26.04% | Reiterates | a year ago |
Biogen IncBIIB | 3 | Strong Buy | $292.00 | N/A | Reiterates | a year ago |
Vertex Pharmaceuticals IncVRTX | 1 | Strong Buy | $370.00 | N/A | Reiterates | 2 years ago |
Bioverativ IncBIVV | 1 | Buy | N/A | N/A | Upgrades | 9 years ago |
G1 Therapeutics IncGTHX | 1 | Buy | $31.00 | N/A | Initiates Coverage On | 9 years ago |
Ovid Therapeutics IncOVID | 1 | Buy | N/A | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.